Shawver Laura 4
4 · ARS Pharmaceuticals, Inc. · Filed Apr 8, 2025
Insider Transaction Report
Form 4
Shawver Laura
Director
Transactions
- Sale
Common Stock
2025-04-07$12.30/sh−50,002$615,075→ 210,346 total - Exercise/Conversion
Stock Option (Right to Buy)
2025-04-07−22,509→ 51,555 totalExercise: $4.85Exp: 2032-01-31→ Common Stock (22,509 underlying) - Exercise/Conversion
Common Stock
2025-04-07$4.85/sh+27,493$133,341→ 260,348 total - Exercise/Conversion
Common Stock
2025-04-07$4.85/sh+22,509$109,169→ 232,855 total - Exercise/Conversion
Stock Option (Right to Buy)
2025-04-07−27,493→ 24,062 totalExercise: $4.85Exp: 2032-01-31→ Common Stock (27,493 underlying)
Footnotes (3)
- [F1]The shares reported on this Form 4 were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 16, 2024.
- [F2]The weighted average sale price for the transaction reported was $12.301 and the range of prices were between $12.0063 and $12.64. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
- [F3]Immediately exercisable.